Myeloproliferative Neoplasms

被引:267
作者
Spivak, Jerry L. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Hematol Div, Baltimore, MD 21205 USA
关键词
HEMATOPOIETIC STEM-CELLS; POLYCYTHEMIA VERA MYELOFIBROSIS; RISK ESSENTIAL THROMBOCYTHEMIA; PROGNOSTIC SCORING SYSTEM; STAT PATHWAY ACTIVATION; ACUTE MYELOID-LEUKEMIA; THROMBOPOIETIN RECEPTOR; BONE-MARROW; PLATELET ACTIVATION; MOLECULAR RESPONSES;
D O I
10.1056/NEJMra1406186
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The myeloproliferative neoplasms - polycythemia vera, essential thrombocytosis, and primary myelofibrosis - are unique hematopoietic stem-cell disorders that share mutations that constitutively activate the physiologic signal-transduction pathways responsible for hematopoiesis (Table 1). Consequently, these disorders engage in phenotypic mimicry among themselves, as well as with myeloid neoplasms and even benign hematopoietic disorders. In contrast to the myeloid neoplasms, the myeloproliferative neoplasms have a natural history, with supportive care alone, that is usually measured in decades rather than years. 1 However, a facade of benign myeloproliferation masks a clone of transformed hematopoietic stem cells capable of expansion and transformation to an aggressive form of bone marrow failure or acute leukemia, albeit at varying frequencies in each of these disorders. In addition to phenotypic mimicry, each type of myeloproliferative neoplasm is capable of evolving into another type, making diagnosis, risk assessment, and therapeutic choices difficult. Furthermore, despite more than a century of scrutiny, the pathogenesis of myeloproliferative neoplasms has been enigmatic, and therapy largely supportive. Recently, however, driver mutations have been identified in more than 90% of patients with myeloproliferative neoplasms, providing substantial insight into their pathogenesis. The current challenge is to integrate this new knowledge with the accumulated decades of clinical knowledge to improve diagnosis, risk assessment, and therapy.
引用
收藏
页码:2168 / 2181
页数:14
相关论文
共 112 条
[1]   Aging-Induced Stem Cell Mutations as Drivers for Disease and Cancer [J].
Adams, Peter D. ;
Jasper, Heinrich ;
Rudolph, K. Lenhard .
CELL STEM CELL, 2015, 16 (06) :601-612
[2]   Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera [J].
Alvarez-Larran, Alberto ;
Pereira, Arturo ;
Cervantes, Francisco ;
Arellano-Rodrigo, Eduardo ;
Hernandez-Boluda, Juan-Carlos ;
Ferrer-Marin, Francisca ;
Angona, Anna ;
Gomez, Montse ;
Muina, Begona ;
Guillen, Helga ;
Teruel, Anabel ;
Bellosillo, Beatriz ;
Burgaleta, Carmen ;
Vicente, Vicente ;
Besses, Carles .
BLOOD, 2012, 119 (06) :1363-1369
[3]   Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia [J].
Alvarez-Larran, Alberto ;
Cervantes, Francisco ;
Pereira, Arturo ;
Arellano-Rodrigo, Eduardo ;
Perez-Andreu, Virginia ;
Hernandez-Boluda, Juan-Carlos ;
Ayats, Ramon ;
Salvador, Carlos ;
Muntanola, Ana ;
Bellosillo, Beatriz ;
Vicente, Vicente ;
Hernandez-Nieto, Luis ;
Burgaleta, Carmen ;
Xicoy, Blanca ;
Besses, Carlos .
BLOOD, 2010, 116 (08) :1205-1210
[4]   Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms [J].
Anand, Shubha ;
Stedham, Frances ;
Beer, Philip ;
Gudgin, Emma ;
Ortmann, Christina A. ;
Bench, Anthony ;
Erber, Wendy ;
Green, Anthony R. ;
Huntly, Brian J. P. .
BLOOD, 2011, 118 (01) :177-181
[5]   Clinical implications of the JAK2 V617F mutation in essential thrombocythemia [J].
Antonioli, E ;
Guglielmelli, P ;
Pancrazzi, A ;
Bogani, C ;
Verrucci, M ;
Ponziani, V ;
Longo, G ;
Bosi, A ;
Vannucchi, AM .
LEUKEMIA, 2005, 19 (10) :1847-1849
[6]   Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms [J].
Arranz, Lorena ;
Sanchez-Aguilera, Abel ;
Martin-Perez, Daniel ;
Isern, Joan ;
Langa, Xavier ;
Tzankov, Alexandar ;
Lundberg, Pontus ;
Muntion, Sandra ;
Tzeng, Yi-Shiuan ;
Lai, Dar-Ming ;
Schwaller, Juerg ;
Skoda, Radek C. ;
Mendez-Ferrer, Simon .
NATURE, 2014, 512 (7512) :78-+
[7]   The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances [J].
Barbui, T. ;
Thiele, J. ;
Gisslinger, H. ;
Finazzi, G. ;
Vannucchi, A. M. ;
Tefferi, A. .
BLOOD REVIEWS, 2016, 30 (06) :453-459
[8]   Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm [J].
Beer, Philip A. ;
Delhommeau, Francois ;
LeCouedic, Jean-Pierre ;
Dawson, Mark A. ;
Chen, Edwin ;
Bareford, David ;
Kusec, Rajko ;
McMullin, Mary Frances ;
Harrison, Claire N. ;
Vannucchi, Alessandro M. ;
Vainchenker, William ;
Green, Anthony R. .
BLOOD, 2010, 115 (14) :2891-2900
[9]   Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones [J].
Beer, Philip A. ;
Jones, Amy V. ;
Bench, Anthony J. ;
Goday-Fernandez, Andrea ;
Boyd, Elaine M. ;
Vaghela, Krishna J. ;
Erber, Wendy N. ;
Odeh, Bassam ;
Wright, Christine ;
McMullin, Mary Frances ;
Cullis, Jonathan ;
Huntly, Brian J. P. ;
Harrison, Claire N. ;
Cross, Nicholas C. P. ;
Green, Anthony R. .
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (06) :904-908
[10]   INCREASED INCIDENCE OF ACUTE-LEUKEMIA IN POLYCYTHEMIA-VERA ASSOCIATED WITH CHLORAMBUCIL THERAPY [J].
BERK, PD ;
GOLDBERG, JD ;
SILVERSTEIN, MN ;
WEINFELD, A ;
DONOVAN, PB ;
ELLIS, JT ;
LANDAW, SA ;
LASZLO, J ;
NAJEAN, Y ;
PISCIOTTA, AV ;
WASSERMAN, LR .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (08) :441-447